Related Experiment Video
Updated: Jun 24, 2026
09:43
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
Treatment for Epstein-Barr virus-associated PTLD.
1Division of Pediatric Hematology/Oncology, Nationwide Children's Hospital, Columbus, OH 43205, USA. Thomas.gross@nationwidechildrens.org
Herpes : the Journal of the IHMF
|March 25, 2009
Summary
Epstein-Barr virus (EBV) drives post-transplant lymphoproliferative disease (PTLD) due to poor T-cell control. Research focuses on better risk prediction, preemptive treatments, and effective therapies for PTLD.
Area of Science:
- * Transplantation Immunology
- * Oncology
- * Infectious Diseases
Background:
- * The link between Epstein-Barr virus (EBV) and post-transplant lymphoproliferative disease (PTLD) is well-established in transplant recipients.
- * PTLD pathogenesis involves inadequate EBV-specific cytotoxic T-cell control over EBV-infected B-cells.
- * PTLD continues to be a major cause of illness and death in transplant patients.
Purpose of the Study:
- * To highlight critical research areas for improving PTLD management.
- * To address the clinical challenge of selecting optimal therapies for PTLD.
- * To identify strategies for reducing PTLD morbidity and mortality.
Main Methods:
- * Review of existing knowledge on EBV and PTLD pathogenesis.
- * Identification of key areas for future clinical investigation and therapeutic development.
- * Analysis of obstacles hindering progress in PTLD treatment.
Main Results:
- * Current understanding points to impaired T-cell immunity as the core issue in PTLD.
- * Several therapeutic avenues require further investigation, including immunosuppression reduction, risk stratification, preemptive strategies, rituximab utility, and novel treatments for refractory disease.
- * Disease and patient heterogeneity, along with varied treatment approaches, present significant challenges.
Conclusions:
- * PTLD remains a significant clinical challenge despite understanding its association with EBV.
- * Further research is essential to refine risk prediction, develop preemptive therapies, and optimize treatment strategies for PTLD.
- * Enhanced collaboration among specialists and large-scale prospective trials are crucial for advancing PTLD care.
Related Concept Videos
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:26Tonsillitis II: Management
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
01:30Acute Pharyngitis
Introduction
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
01:28Pleural Effusion II: Symptoms and Management
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: